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Abstract: The role of donor-specific antibodies (DSA) to human leukocyte antigens and the
burden of antibody-mediated rejection (AMR) in lung transplantation remain enigmatic. Over
the past several years, evidence has been emerging that humoral immunity plays an important
role in the development of both acute and chronic lung allograft dysfunction (CLAD). Multiple case reports and case series have identified lung allograft recipients with clinical findings
consistent with acute AMR. However, there is currently no widely accepted definition for AMR
in lung transplantation, and this has been a significant barrier to furthering our understanding of this form of rejection. Nonetheless, the development of DSA after transplantation has
consistently been identified as an independent risk factor for persistent and high-grade acute
cellular rejection and CLAD. This has raised the possibility that chronic AMR may be a distinct
phenotype of CLAD although evidence supporting this paradigm is still lacking. Additionally,
antibodies to lung-restricted self-antigens (collagen V and K-α 1 tubulin) have been associated
with primary graft dysfunction early and the development of CLAD late after transplantation,
and emerging evidence underscores significant interactions between autoimmunity and alloimmunity after transplantation. There is currently an active International Society for Heart and
Lung Transplantation working group that is developing an operational definition for AMR in
lung transplantation. This will be critical to improve our understanding of this form of rejection
and conduct clinical trials to identify optimal treatment strategies. This review will summarize
the literature on DSA and AMR in lung transplantation and discuss the impact of antibodies to
self-antigens on lung allograft dysfunction.
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Over the past 30 years, lung transplantation has become the ultimate treatment for
patients with end-stage lung disease. The number of lung transplant procedures
has continued to increase, and more than 3,600 procedures were reported to the
International Society for Heart and Lung Transplantation (ISHLT) Registry in 2011.1
Survival after lung transplantation has been slowly improving; however, long-term
outcomes remain disappointing with a median survival of 6.1 years in the most
recent era (June 2004 – December 2011).1 This is in contrast to allograft survival
after kidney and liver transplantation where the median survival is over 9 years after
deceased-donor kidney transplantation and over 12 years after living-donor kidney
and deceased-donor liver transplantation.2,3 The major causes of death within the first
year after lung transplantation are allograft failure and non-cytomegalovirus infections. Beyond the first year after transplantation, chronic lung allograft dysfunction
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(CLAD), coded in the ISHLT Registry as bronchiolitis or late
allograft failure, is the leading cause of mortality, accounting
for .40% of deaths.1 This clearly demonstrates that CLAD
is the primary obstacle to better long-term outcomes after
lung transplantation.
It is widely believed that rejection is the underlying cause
of most forms of CLAD, and traditionally, solid-organ transplant rejection has been regarded as a predominantly T-cell
mediated process. Accordingly, standard immunosuppressive
regimens consisting of a calcineurin inhibitor, a cell cycle
inhibitor, and corticosteroids targeting T-cell proliferation
and function have made organ transplantation a clinical
reality.2,3 However, emerging data suggest that humoral
immunity may play an important and previously underappreciated role in rejection and chronic allograft dysfunction.
Antibody-mediated rejection (AMR) is a widely accepted
and well-defined form of rejection after kidney and heart
transplantation, and the Pathology Council of the ISHLT has
recently proposed a summary statement on the pathology of
AMR after lung transplantation.4–7 This review will discuss
the different manifestations of AMR in lung transplantation,
including hyperacute rejection, acute AMR, donor-specific
antibodies (DSA) to human leukocyte antigens (HLA), and
antibodies to self-antigens and their role in the development
of CLAD.

Hyperacute rejection
Hyperacute rejection results from circulating preexisting
DSA and occurs within minutes or hours of transplantation
and perfusion of the allograft. Clinically, hyperacute rejection after lung transplantation is characterized by fulminant
allograft dysfunction with severe gas-exchange impairment,
hemorrhagic pulmonary edema, and diffuse radiographic
infiltrates.8 Preformed DSA bind to HLA on donor endothelial cells, resulting in the activation of the classical complement cascade and leading to the formation of the membrane
attack complex and endothelial cell injury. The development
and refinement of solid-phase antibody detection assays have
significantly improved the ability to detect and identify the
specificity of HLA antibodies before transplantation. Using
these specificities and the potential donor’s HLA type, crossmatch results can be predicted accurately before donor organ
acceptance. This virtual crossmatch improves donor selection
for allosensitized patients and minimizes the risk of HLA
incompatible transplants; as a result, hyperacute rejection
has become rare. Nonetheless, hyperacute rejection after
lung transplantation is a widely accepted form of rejection
and demonstrates that circulating antibodies can severely
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injure the lung allograft, often resulting in allograft failure.
The pathology of hyperacute rejection is notable for severe
acute lung injury with diffuse microvascular thrombi, neutrophilic infiltration of the alveolar septae, capillaritis, fibrinoid
necrosis, and hemorrhagic infarction.9–11 Electron micro
scopy, when performed, demonstrates that endothelial cells
are the focal point of immunologic injury.12 Furthermore,
immunostaining for immunoglobulin G or complement
component 4d (C4d) illustrates an antibody and complementmediated endothelial cell injury process.12
Outcomes after hyperacute rejection are generally poor,
and allograft loss is common. Intensive treatment regimens
focusing on depleting antibodies or mitigating antibody-mediated injury have been used with mixed results. Bittner et al
described a case report of successful treatment of hyperacute
rejection in a single lung transplant recipient with a regimen
consisting of plasmapheresis, antithymocyte globulin, and
cyclophosphamide.13 Dawson et al described a case report
of a bilateral lung transplant recipient who developed hyperacute rejection refractory to plasma exchange, rituximab,
bortezomib, and intravenous immunoglobulin (IVIG) who
responded well to eculizumab.14 Rituximab, a chimeric monoclonal antibody to CD20, a cell-surface antigen expressed on
mature B-cells, induces B-cell depletion through complementdependent cytotoxicity and antibody-dependent cytotoxicity.
However, plasma cells, the predominant antibody-producing
cells, do not express CD20; this raises an important potential limitation to the use of rituximab in AMR. Bortezomib,
a proteasome inhibitor, induces plasma cell apoptosis and
offers a theoretical advantage. Eculizumab is a humanized
monoclonal antibody that targets complement component
5 (C5) and inhibits the cleavage of C5 into C5a and C5b,
thereby preventing formation of the membrane attack complex (C5b–C9). This first-in-class complement inhibitor is
approved for use in paroxysmal nocturnal hemoglobinuria and
atypical hemolytic uremic syndrome, two uncommon diseases
of complement dysregulation. Further clinical investigation
of its use in complement-mediated allograft injury including
hyperacute rejection and acute AMR is warranted.

Acute AMR
The diagnostic criteria for lung allograft rejection were
revised in 2007 and classified four forms of rejection: acute
rejection; lymphocytic bronchiolitis; obliterative bronchiolitis
(OB); and chronic vascular rejection.15 However, there was
no consensus on the features or clinicopathologic diagnostic
criteria for AMR in lung transplant recipients. The National
Conference to Assess Antibody-Mediated Rejection in Solid
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Organ Transplantation has proposed a general paradigm of
humoral responses applicable to all organs to help facilitate
further investigation.16 The National Conference defined
AMR according to the following criteria: circulating DSA;
C4d deposition; tissue pathology; and clinical allograft
dysfunction.16 C4d deposition in lung allografts has been
demonstrated in cases of AMR; however, it may be nonspecific and can be seen with acute cellular rejection in the
absence of DSA or other forms of lung injury. Furthermore,
C4d staining and interpretation is technically difficult to
perform reliably with reproducible results.17–21 The ISHLT
Pathology Council summary statement concluded that
the diagnosis of pulmonary AMR should require: clinical
allograft dysfunction; circulating DSA; and abnormal histopathologic findings.7 Discussion of C4d staining is included
in the summary statement, but not required by the ISHLT
Pathology Council for the diagnosis of pulmonary AMR.7
There have been multiple case reports and case series of
lung transplant recipients presenting with clinical findings
consistent with AMR. Early reports included clinical presentations of allograft dysfunction presenting with diffuse
alveolar hemorrhage, capillaritis, and/or C4d deposition
did not identify DSA although less sensitive HLA antibody
detection assays were used.22,23 In such cases, it is possible
that DSA may not have be detectable in the peripheral circulation because the antibodies are adsorbed in the allograft.
Furthermore, non-HLA antibodies against endothelial cells
were identified in one series and there was clinical improvement with plasmapheresis implying humorally mediated
injury as the mechanism of allograft dysfunction.23 In addition, this does not rule out the possibility that some of the antibodies may have been autoantibodies and autoimmunity has
emerged as a risk factor for chronic allograft dysfunction.24
The role of autoimmunity in acute and chronic allograft
dysfunction will be discussed in “Role of autoimmunity
and antibodies to self-antigens in primary graft dysfunction
and CLAD”.
Subsequently, two case reports from independent centers described similar clinicopathological features of acute
AMR.25,26 In both cases, the recipient was not allosensitized
prior to transplantation and had a negative direct crossmatch
at the time of transplant. Both developed allograft dysfunction,
capillaritis, C4d deposition, and new circulating DSA. In the
first case, there was no response to high dose corticosteroids
and basiliximab, but there was a good response to rituximab.25
The second patient was treated with a combination of IVIG,
plasmapheresis, and rituximab with resolution of the allograft
dysfunction and long-term clinical stability.26
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In 2013, our center reported a case series of patients with
AMR and proposed a strict definition of acute AMR in lung
transplant recipients.27 This definition was based on criteria
proposed by the ISHLT Pathology Council and the National
Conference to Assess Antibody-Mediated Rejection in
Solid Organ Transplantation. We defined acute AMR as:
allograft dysfunction; circulating DSA; tissue pathology;
and capillary endothelial C4d deposition (Figure 1). We
conducted a retrospective cohort study at our center that
included 501 lung transplant procedures from January 1,
2004–June 30, 2012. During that time, we identified 21 lung
recipients meeting this stringent definition of acute AMR.
All patients had diffuse, bilateral pulmonary infiltrates on
imaging and other causes of acute allograft dysfunction were
ruled out (Figure 2). The predominant pathology was acute
lung injury, and eleven of the 21 patients had capillaritis
while ten did not.
Based on the definition to identify cases, capillary
endothelial C4d deposition was seen in all patients. AMR
was diagnosed a median of 258 days after transplantation,
14 in the first year and the other seven more than 1 year after
transplant. Also, 14 of the 21 patients required mechanical
ventilation, and six died of refractory AMR during their index
hospitalization. Of the 15 patients who survived their index
episode of AMR, one had preexisting CLAD and 13 of the
remaining 14 developed CLAD. Nine of the 15 patients who
survived their index episode of acute AMR died during the
follow-up period. Recipients who cleared the DSA had a
better survival than those with persistent DSA.
During the study period, our treatment regimens were
individualized, and the specific treatment depended on the
clinical course; these included antithymocyte globulin, IVIG,
plasmapheresis, rituximab, bortezomib, and/or eculizumab
in various combinations. The high mortality and near universal development of CLAD among survivors in this cohort

Figure 1 Pathologic findings in patient with acute pulmonary AMR.
Notes: (A) Transbronchial biopsy specimen from a patient with acute AMR
demonstrating capillaritis (arrows with solid lines) and hyaline membrane formation
(arrow with dotted line). Original magnification 400×. (B) Transbronchial biopsy
specimen from a patient with acute AMR demonstrating circumferential C4d staining
of the capillary endothelium (arrows). Original magnification 600×.
Abbreviations: AMR, antibody-mediated rejection; C4d, component 4d.
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Figure 2 Radiological findings in patient with acute pulmonary AMR.
Notes: (A) Diffuse bilateral infiltrates on chest radiograph in a lung recipient
with acute AMR. (B) Bilateral infiltrates with ground-glass opacities on computed
tomography of the chest in the same lung recipient with AMR.
Abbreviation: AMR, antibody-mediated rejection.

underscore the significant clinical impact of acute AMR in
lung transplant recipients.
The optimal treatment regimen for patients with acute AMR
is not currently known. Given the lack of a widely accepted
definition of acute AMR after lung transplantation, it is difficult
to determine from the published literature whether reported
cases all had the same syndrome of allograft dysfunction.
Furthermore, treatment in all cases and series has been individualized and highly dependent on the clinical course. This
makes comparing the relative efficacy of different regimens
impossible. Nonetheless, different combinations of plasmapheresis, IVIG, rituximab, antithymocyte globulin, bortezomib,
and eculizumab have been given to treat pulmonary AMR.27–31
There is immunological rationale for combination therapy,
including inhibiting DSA-mediated complement activation with
eculizumab, depleting circulating DSA with plasmapheresis,
decreasing antibody production by targeting plasma cells with
bortezomib, and decreasing plasma cell development and
activation with rituximab. These more targeted therapies are
likely to be given in combination with therapies with broader
spectrums of activity, including IVIG, high-dose corticosteroids, and antithymocyte globulin. Which of these therapies
or combinations of therapies is most effective remains to be
determined and will require randomized controlled trials with
a strict definition of acute AMR in the future.
A multidisciplinary ISHLT working group, consisting of
experts in pulmonary medicine, pathology, and immunology
is currently reviewing the published literature and professional experiences to develop a definition for AMR after lung
transplantation. This will standardize the nomenclature and
facilitate the necessary clinical and immunological research
to better understand AMR and ultimately identify effective
preventative and treatment strategies.

DSA and CLAD
Traditionally, OB has been the histologic hallmark of chronic
lung allograft rejection. However, histologic confirmation of
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OB is difficult because of the patchy nature of the disease
and the small samples obtained with transbronchial lung
biopsies, so bronchiolitis obliterans syndrome (BOS),
defined and staged according to changes in spirometry, has
served as the clinical surrogate for OB. More recently, there
has been a paradigm shift with the introduction of the more
encompassing term “chronic lung allograft dysfunction,”
which includes BOS and restrictive allograft syndrome
(RAS).32 There has been a strong association between DSA
and BOS, but it remains unclear if DSA play a role in RAS
development.
An association between the development of HLA antibodies and BOS has been recognized since the late 1990s, and
more recent clinical data linked HLA antibodies, and DSA in
particular, with persistent and high-grade acute cellular rejection and lymphocytic bronchiolitis.33–37 In addition, a recent
large cohort analysis identified the development of HLA
antibodies as an independent risk factor for mortality after
transplant.38 Despite these clinical data, it remains unclear if
HLA antibodies cause BOS or if they are an epiphenomenon
of the cellular immune response. However, in vitro and animal studies suggest that HLA (and major histocompatibility
complex [MHC]) antibodies play a pathogenic role; HLA
antibodies have been shown to induce airway epithelial cell
proliferation, lead to the release of fibrogenic growth factors,
and result in epithelial cell apoptosis.39 Additionally, MHC
antibodies have been shown to induce airway obliteration
when systemically administered in a murine heterotopic
tracheal transplant model and cause small airway obliteration
when delivered intrabronchially into native lungs.40,41 Given
the experimental and clinical data suggesting a role for HLA
antibodies in the development of BOS and CLAD, there has
been an intensified focus on the role of these antibodies in
lung transplant recipients.
Our center examined the outcomes of lung transplant
recipients who developed DSA and the response to treatment
with either IVIG or IVIG and rituximab.37 In this series of
116 recipients, 65 (56%) developed de novo DSA during the
study period. There was no statistically significant difference
in the incidence of acute cellular rejection, lymphocytic
bronchiolitis, or BOS between those who developed DSA and
were treated and those who did not develop DSA. However,
since this was not a randomized controlled trial, it is not
clear if this finding reflects a treatment effect. Nonetheless,
this study demonstrated that patients who had successful
depletion of DSA (ie, DSA was no longer detectable after
treatment) had greater freedom from BOS and better survival
than those who had persistent DSA.
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In a recent large single center cohort study, DSA development was a significant risk factor for mortality but not BOS.38
In contrast, non-DSA HLA antibodies were significant risk
factors for both BOS and mortality.38 Reasons for the lack
of association between DSA and BOS in this study are not
clear, but the results demonstrate that non-DSA HLA antibodies can also increase the risk of BOS. In fact, pretransplant
non-DSA HLA antibodies and major histocompatibility
complex (MHC) class I-related chain A antibodies have been
associated with an increased risk of BOS.42 Clearly, additional studies and randomized controlled trials are needed to
better understand the role of HLA and non-HLA antibodies
in BOS development and to critically examine the potential
benefit of DSA depletion in clinically stable lung transplant
recipients. Of note, a multicenter randomized controlled trial
examining the efficacy of rituximab as induction immunosuppression in pediatric lung transplant recipients is being
planned by the Clinical Trials in Organ Transplantation in
Children network.
In addition, since CLAD is the leading cause of death
beyond the first year after lung transplantation and its
pathogenesis remains unclear, further investigation into the
potential role of DSA in the development of a chronic form
of AMR is indicated. It is possible that RAS may represent
chronic AMR; however, data linking RAS to humoral
immune responses are lacking to date. Clearly, this is an area
of ongoing investigation.

Role of autoimmunity and antibodies
to self-antigens in primary graft
dysfunction and CLAD
Autoimmunity is the hallmark of systemic autoimmune
diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and the vasculitides. Many of these diseases
are thought to result from a loss of immunologic tolerance
and the development of immune responses to self-antigens.43
Antibodies to myosin, vimentin, and heat-shock proteins after
heart transplantation and to angiotensin type 1 receptor after
kidney transplantation have been associated with allograft
dysfunction.44–47 More recent studies have demonstrated a
potential role for autoimmunity in both primary graft dysfunction and BOS. For example, peripheral blood mononuclear cells taken from lung transplant recipients have been
found to be reactive against self-antigens, demonstrating the
presence of T-cell mediated autoimmunity.48
The two self-antigens that have received the most
attention in lung transplant recipients are type V collagen
(Col V) and K-α 1 tubulin. Col V and K-α 1 tubulin are
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both expressed on airway epithelial cells, and antibodies against these self-antigens have been associated with
primary graft dysfunction and BOS. 49–51 Furthermore,
the development of DSA has been associated with the
development of antibodies to self-antigens, and it has been
proposed that alloimmune responses in the form of DSA
may induce an autoimmune response and contribute to the
pathogenesis of BOS.52 It has also been demonstrated that
lung transplant recipients who were treated with antibodydirected therapy and cleared the antibodies to self-antigens
are significantly less likely to develop BOS compared to
those who had persistent antibodies to self-antigens.24 The
precise mechanism by which autoimmunity contributes
to acute and chronic allograft dysfunction and how to use
these emerging data clinically remains an area of ongoing
investigation.

Conclusion
CLAD remains the major cause of death in lung transplant
recipients beyond the first year after transplantation. Although
T-cell inhibition has been the primary goal of immunosuppression to prevent allograft rejection, it is becoming increasingly evident that AMR and the development of DSA and
subsequent CLAD play a significant role in allograft and
patient survival. Additionally, antibodies to self-antigens
appear to play a role in the development of CLAD. As the
understanding of the pathophysiology and clinical science
advances, further investigations into treatment strategies for
antibody depletion and immune modulation will be possible.
This is crucial to identify strategies to improve outcomes
after lung transplantation.
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